BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Okamoto S, Iida M, Hamad N, Duarte FB, Sureda A, Srivastava A, Galeano S, Chao N, Rondelli D, Flowers ME. American Society of Transplantation and Cellular Therapy International Affair Committee: Report of 3(rd) Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting. Transplant Cell Ther 2023:S2666-6367(23)01134-X. [PMID: 36921918 DOI: 10.1016/j.jtct.2023.02.024] [Reference Citation Analysis]
2 Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, de Latour RP, Perić Z, Ruggeri A, Snowden JA, Sureda A. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant 2023;:1-12. [PMID: 36879108 DOI: 10.1038/s41409-023-01943-3] [Reference Citation Analysis]
3 Garrigós MM, Oliveira FA, Nucci MP, Mamani JB, Dias OFM, Rego GNA, Junqueira MS, Costa CJS, Silva LRR, Alves AH, Valle NME, Marti L, Gamarra LF. Bioluminescence Imaging and ICP-MS Associated with SPION as a Tool for Hematopoietic Stem and Progenitor Cells Homing and Engraftment Evaluation. Pharmaceutics 2023;15:828. [DOI: 10.3390/pharmaceutics15030828] [Reference Citation Analysis]
4 Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. Prevention and management of secondary central nervous system lymphoma. Haematologica 2023;108:673-89. [PMID: 36384246 DOI: 10.3324/haematol.2022.281457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Castiello MC, Ferrari S, Villa A. Correcting inborn errors of immunity: From viral mediated gene addition to gene editing. Semin Immunol 2023;66:101731. [PMID: 36863140 DOI: 10.1016/j.smim.2023.101731] [Reference Citation Analysis]
6 Kumar R, Salas M, Atenafu E, Pasic I, Bascom O, Wilson L, Lam W, Law A, Chen C, Novitzky-basso I, Kim D, Gerbitz A, Viswabandya A, Michelis F, Lipton J, Mattsson J, Alibhai S. HCT Frailty Scale for Younger and Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation.. [DOI: 10.21203/rs.3.rs-2551208/v1] [Reference Citation Analysis]
7 Milczarek S, Kulig P, Zuchmańska A, Baumert B, Osękowska B, Bielikowicz A, Wilk-Milczarek E, Machaliński B. Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter. Cancers (Basel) 2023;15. [PMID: 36831679 DOI: 10.3390/cancers15041338] [Reference Citation Analysis]
8 Clark A, Thomas S, Hamblin A, Talley P, Kulasekararaj A, Grinfeld J, Speight B, Snape K, McVeigh TP, Snowden JA. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). Br J Haematol 2023. [PMID: 36786081 DOI: 10.1111/bjh.18682] [Reference Citation Analysis]
9 Styczyński J, Słomka A, Łęcka M, Albrecht K, Romiszewski M, Pogorzała M, Kubicka M, Kuryło-Rafińska B, Tejza B, Gadomska G, Kolańska-Dams E, Michalska M, Żekanowska E. Soluble Hemojuvelin and Ferritin: Potential Prognostic Markers in Pediatric Hematopoietic Cell Transplantation. Cancers (Basel) 2023;15. [PMID: 36831385 DOI: 10.3390/cancers15041041] [Reference Citation Analysis]
10 Servais S, Baron F, Lechanteur C, Seidel L, Baudoux E, Briquet A, Selleslag D, Maertens J, Poire X, Schroyens W, Graux C, De Becker A, Zachee P, Ory A, Herman J, Kerre T, Beguin Y. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis. Front Immunol 2023;14:1106464. [PMID: 36817464 DOI: 10.3389/fimmu.2023.1106464] [Reference Citation Analysis]
11 de Almeida TD, Evangelista FCG, Sabino ADP. Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity. Future Pharmacology 2023;3:162-179. [DOI: 10.3390/futurepharmacol3010012] [Reference Citation Analysis]
12 Mariottini A, Bulgarini G, Cornacchini S, Damato V, Saccardi R, Massacesi L. Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update. Bioengineering (Basel) 2023;10. [PMID: 36829670 DOI: 10.3390/bioengineering10020176] [Reference Citation Analysis]
13 Acerbis A, Orofino G, Campodonico E, Del Poggio A, Xue E, di Matteo F, Spelta G, Bruno A, Falini A, Ciceri F, Peccatori J, Greco R. Pre-engraftment neurological impairment in allogeneic stem cell transplant: A case report of atypical posterior reversible encephalopathy syndrome with pontine involvement. Front Transplant 2023;1. [DOI: 10.3389/frtra.2022.1089995] [Reference Citation Analysis]
14 Crocchiolo R, Rombolà G. Human Leucocyte Antigen System and Selection of Unrelated Hematopoietic Stem Cell Donors: Impact of Patient-Donor (Mis)matching and New Challenges with the Current Technologies. J Clin Med 2023;12. [PMID: 36675576 DOI: 10.3390/jcm12020646] [Reference Citation Analysis]
15 Köksal M, Kersting L, Schoroth F, Garbe S, Koch D, Scafa D, Sarria GR, Leitzen C, Heine A, Holderried T, Brossart P, Zoga E, Attenberger U, Schmeel LC. Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy. J Cancer Res Clin Oncol 2023. [PMID: 36607428 DOI: 10.1007/s00432-022-04565-2] [Reference Citation Analysis]
16 Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms? Int J Mol Sci 2023;24. [PMID: 36674573 DOI: 10.3390/ijms24021045] [Reference Citation Analysis]
17 Gong S, Chen C, Chen K, Yang R, Wang L, Yang K, Hu J, Nie L, Su T, Xu Y, He X, Yang L, Xiao H, Fu B. Alternative Transplantation With Post-Transplantation Cyclophosphamide in Aplastic Anemia: A Retrospective Report From the BMF-WG of Hunan Province, China. Transplant Cell Ther 2023;29:48.e1-7. [PMID: 36272527 DOI: 10.1016/j.jtct.2022.10.006] [Reference Citation Analysis]
18 Mina SA, Muhsen IN, Hashmi SK. Challenges and opportunities in shared care for international patients treated with cellular therapy for nonmalignant disease. Curr Opin Hematol 2023;30:22-7. [PMID: 36539362 DOI: 10.1097/MOH.0000000000000742] [Reference Citation Analysis]
19 Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, Kröger N, Yegin ZA, Tan SM, Hayden PJ, McLornan DP, Yakoub-Agha I; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol 2023;98:112-21. [PMID: 36266607 DOI: 10.1002/ajh.26764] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sorigue M, Kuittinen O. Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas. Cancers (Basel) 2022;15. [PMID: 36612216 DOI: 10.3390/cancers15010220] [Reference Citation Analysis]
21 Castagna L, Bono R, Tringali S, Sapienza G, Santoro A, Indovina A, Tarantino V, Di Noto L, Maggio A, Patti C. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. Front Med (Lausanne) 2022;9:1072192. [PMID: 36561713 DOI: 10.3389/fmed.2022.1072192] [Reference Citation Analysis]
22 Xue E, Minniti A, Alexander T, Del Papa N, Greco R, of the Ebmt OBOTADWP. Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches. Cells 2022;11:3346. [DOI: 10.3390/cells11213346] [Reference Citation Analysis]
23 Adam Z, Pour L, Krejčí M, Zeman D, Vlčková E, Krtička M, Šlampa P, Štěpánková S, Romanová G, Adamová Z, Vaníček J, Řehák Z, Koukalová R, Matušková V, Král Z, Červinek L, Sandecká V. Plasma cell neoplasms, multiple myeloma, solitary plasmocytoma a plasma cell leukemia. Clinical symptoms, diagnostic criteria and therapy. Onkologie 2022;16:7-32. [DOI: 10.36290/xon.2022.054] [Reference Citation Analysis]
24 Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ, Snowden JA, Sharrack B. Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? Pract Neurol 2022:pn-2022-003531. [PMID: 36162855 DOI: 10.1136/pn-2022-003531] [Reference Citation Analysis]
25 Ma R, Liu X, Chang Y. Allogeneic haematopoietic stem cell transplantation for acute lymphoblastic leukaemia: current status and future directions mainly focusing on a Chinese perspective. Expert Review of Hematology. [DOI: 10.1080/17474086.2022.2125375] [Reference Citation Analysis]
26 Heesen C, Kaufmann M, Janson D, Häußler V, Kröger N, Friese MA. Stammzelltransplantation bei Multipler Sklerose - wo stehen wir? InFo Neurologie 2022;24:42-51. [DOI: 10.1007/s15005-022-3002-0] [Reference Citation Analysis]
27 Moreno-Castaño AB, Salas MQ, Palomo M, Martinez-Sanchez J, Rovira M, Fernández-Avilés F, Martínez C, Cid J, Castro P, Escolar G, Carreras E, Diaz-Ricart M. Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development. Front Immunol 2022;13:1050994. [PMID: 36479117 DOI: 10.3389/fimmu.2022.1050994] [Reference Citation Analysis]